ClearB Therapeutics is focused on developing innovative therapeutic vaccines aimed at achieving a functional cure for chronic hepatitis B (CHB). Their approach leverages engineered bionanoparticles (BNPs) that incorporate hepatitis B surface antigen (HBsAg) with specific clearance epitope target inserts. This strategy is grounded in proprietary insights gained from studying rare instances of infection resolution in patients with chronic hepatitis B. The company is advancing its lead candidate, CLB-3000, through clinical trials while also exploring additional therapeutic avenues to address the significant global health challenge posed by CHB, which affects approximately 250 million individuals worldwide.

In collaboration with Adjuvance Technologies, ClearB has licensed a novel saponin adjuvant, TQL-1055, which is designed to enhance the immune response to their HBsAg variants, CLB-405 and CLB-505. This adjuvant aims to improve tolerability while maintaining strong immune stimulation, a critical factor in vaccine efficacy. ClearB's commitment to addressing the complexities of chronic hepatitis B is reflected in their ongoing research and upcoming presentations at major medical conferences, where they will share preclinical data and insights that could inform future combination treatment regimens for this serious viral infection.

United States

ClearB is working to develop therapeutic vaccines designed to redirect patients’ immune systems toward functional cure of hepatitis B.

ClearB Therapeutics

Company Details